Винпоцетин-Сар®

General characteristics. Structure:

Active ingredient: 0,5 g of a Vinpocetine.

Excipients: ascorbic acid, succinic acid, sodium disulphite, sodium chloride, water for injections.

The drug improving metabolic processes in a brain.

Pharmacological properties:

Pharmacodynamics. Improves metabolism of a brain, increasing consumption of glucose and oxygen brain tissues. Increases resistance of cells of a brain to a hypoxia, facilitating transport of oxygen and substrates of a power obesyopecheniye to fabrics (owing to reduction of affinity to it of erythrocytes, strengthening of absorption and metabolism of a glyuyokoza, its switching to energetically more favorable aerobic direction).

Promotes accumulation in fabrics of cyclic adenosinemonophosphate and adenosinetriphosphate (braking of calcium ions - dependent FDE and an adenylatecyclase stimuyolyation), to increase in maintenance of catecholamines in brain tissues. Stimulates the ascending branch of noradrenergichesky system, has antioxidant effect.

Vazodilatiruyushchy action is connected with the direct running-down impact on smooth muscles of vessels preferential of a brain. The Vinpocetine does not cause a phenomenon of "burglarizing", first of all strengthens a krovoyosnabzheniye of ischemic area of a brain, without changing at the same time blood supply of intact areas. Uluchyoshayet microcirculation in a brain due to reduction of aggregation of thrombocytes, decrease in viscosity of blood, increase in deformability of erythrocytes. Raises a cerebral blood stream; reduces resistance of vessels of a brain without significant effect on indicators of system blood circulation (the arterial pressure (AP), MO, heart rate).

Pharmacokinetics. Therapeutic concentration at parenteral administration in plasma of-10-20 mg/ml, distribution volume - 5,3 l/kg. Easily gets through gistogematichesky barriers (including a gematoentsefaletichesky barrier).

Gets into breast milk (0,25% within the first hour), through a placental barrier. A drug elimination half-life - 4,74-5 h Vyvoyoditsya kidneys and intestines in the ratio 3:2. Communication with proteins - 66%, clearance - 66,7 l/h, exceeds the plasma volume of a liver (50 l/h) that demonstrates extrahepatic metabolism.

Indications to use:

Neurology: as symptomatic means at various forms of insufficiency of a brain krovoyoobrashcheniye (an ischemic stroke, a recovery stage of a hemorrhagic stroke, an effect of the had stroke; tranzitorny ischemic attack; vascular dementia; vertebrobazilyarny insufficiency; атеро­склероз brain vessels; posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic vascular diseases of a choroid and retina of an eye (including okklyuyoziya of the central artery or vein of a retina).

Decrease in auditory acuity of perceptual type, Menyer's disease, idiopathic sonitus.

Route of administration and doses:

Intravenously kapelno (speed of infusion should not exceed 80 caps/min.). An initial daily dose - 20 mg (in 0,5-1 l of 0,9% of solution of sodium of chloride or the solutions containing a dextrose). An average daily dose at the body weight of 70 kg - 50 mg. At good tolerance within 2-3 days the dose is raised to the maximum-1 mg/kg/days. A course of treatment - 10 - 14 days.

Parenterally, as a rule, apply in acute cases before improvement of a clinical picture, then pass to administration of drug in the form of tablets.

Hypodermic administration of drug is not allowed! After achievement of improvement pass to administration of drug inside.

Features of use:

In case of initial lengthening of QT of an interval, and also at simultaneous use with the HP extending QT an interval during treatment by a Vinpocetine control is necessary a periodic ECG.

During use of drug it is necessary to keep care during the driving of transport and work with difficult mechanisms.

Use at pregnancy and during breastfeeding. Use of drug is contraindicated.

Side effects:

From cardiovascular system: changes on the electrocardiogram (ST segment depression, udlineyony QT interval); tachycardia, premature ventricular contraction (relationship of cause and effect is not established), lability of DD (decrease is more often).

From the central nervous system: a sleep disorder (sleeplessness, the increased drowsiness); dizziness, a headache, the general weakness (can be manifestation of a basic disease).

From the alimentary system: dryness in a mouth, nausea, heartburn.

Others: skin allergic reactions, the increased sweating, a dermahemia, phlebitis at intravenous administration.

Interaction with other medicines:

The concentrate for preparation of solution for infusion pharmaceutical is incompatible with the heparin, solutions containing amino acids.

Strengthening of hypotensive action at simultaneous use with metildopy is possible (control of the ABP is necessary).

Despite the absence of the data confirming a possibility of interaction it is recommended to observe an osyotorozhnost at simultaneous use with the medicines (M) influencing the central nervyony system, antiaritmika and anticoagulants.

Contraindications:

Hypersensitivity, acute phase of a hemorrhagic stroke, the heavy coronary heart disease (CHD), heavy disturbances of a heart rhythm, pregnancy, the lactation period, age up to 18 years.

With care use drug at arrhythmia, stenocardia, unstable arterial pressure and a poniyozhenny vascular tone. At a hemorrhagic cerebral stroke parenteral administration of a Vinpocetine is allowed only after decrease in the acute phenomena - ordinary in 5 - 7 days

Overdose:

The overdose of the Vinpocetine can be followed by strengthening of dozozavisimy side effects of drug.

Treatment consists in use of hypotensive and antiarrhytmic means under control of the doctor.

Storage conditions:

In the dry, protected from light place at a temperature not above 25 °C. In the place, unavailable to children, the Period of validity 2 years. Not to use after the expiry date specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Concentrate for preparation of solution for infusion of 5 mg/ml. 2 ml in ampoules of neutral glass. 5 ampoules place in a blister strip packaging. 2 blister strip packagings place in a pack from a cardboard. 10 ampoules place in a pack from a cardboard with partitions or lattices, or a separator from a cardboard. 10 ampoules place in a box from a cardboard. Put the application instruction, a knife in each pack or a box ampoule or the scarificator ampoule. In case of use of ampoules with notches, rings of a break or points of a break, the knife ampoule or a skariyofikator ampoule is not put.